Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD19 Double Nickase Plasmid (h): sc-400719-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD19 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD19 Double Nickase Plasmid (h) and CD19 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD19. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD19 Antibody (B-1): sc-390244
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD19 Double Nickase Plasmid (h) | sc-400719-NIC | 20 µg | $410.00 | |||
CD19 Double Nickase Plasmid (h2) | sc-400719-NIC-2 | 20 µg | $410.00 |
CD19 is a B cell–restricted transmembrane glycoprotein that functions as a coreceptor amplifying B cell receptor (BCR) signaling by organizing signaling complexes with CD21 and CD81. Through modulation of PI3K–AKT, MAPK/ERK, and calcium-dependent pathways, CD19 helps set activation thresholds that govern B cell proliferation, differentiation, and antibody responses. CD19 expression is tightly linked to B cell lineage commitment and germinal center dynamics, and its dysregulation is frequently used as a molecular feature in studies of B cell malignancies and immune-mediated pathology. As a surface marker with defined signaling roles, CD19 provides a tractable entry point for dissecting B cell signaling networks and antigen-driven selection.
CD19 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD19 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD19. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD19 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD19-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.